Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yanfei Feng, Zitong Yang & Xin Xu. (2022) c-Met: A Promising Therapeutic Target in Bladder Cancer. Cancer Management and Research 14, pages 2379-2388.
Read now
Read now
Qing-Wen Zhang, Zi-Dan Ye & Lei Shi. (2019) c-Met kinase inhibitors: an update patent review (2014-2017). Expert Opinion on Therapeutic Patents 29:1, pages 25-41.
Read now
Read now
Lanfang Meng, Mengjun Shu, Yaqing Chen, Dexiao Yang, Qun He, Hui Zhao, Zhiyong Feng, Chris Liang & Ker Yu. (2014) A novel lead compound CM-118. Cancer Biology & Therapy 15:6, pages 721-734.
Read now
Read now
Marco Petrillo, Giovanni Scambia & Gabriella Ferrandina. (2012) Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opinion on Investigational Drugs 21:4, pages 451-472.
Read now
Read now
Articles from other publishers (47)
强 赵. (2023) Effect of MMP11 Gene on Diagnosis and Prognosis of Lung Adenocarcinoma. World Journal of Cancer Research 13:02, pages 69-78.
Crossref
Crossref
An-Na Jiang, Bing Wang, Song Wang, Kun Zhao, Hao Wu, Kun Yan, Wei Wu & Wei Yang. (2022) The study of direct and indirect effects of radiofrequency ablation on tumor microenvironment in liver tumor animal model. BMC Cancer 22:1.
Crossref
Crossref
Atukuri Dorababu. (2022) Pyrazolopyrimidines as attractive pharmacophores in efficient drug design: A recent update. Archiv der Pharmazie 355:10, pages 2200154.
Crossref
Crossref
Dong Liang, Chen Yu, Xiaojun Qin, Xingye Yang, Xuhui Dong, Mingzhao Hu, Lupei Du & Minyong Li. (2022) Discovery of small-molecule fluorescent probes for C-Met. European Journal of Medicinal Chemistry 230, pages 114114.
Crossref
Crossref
Dhaneshree Bestinee Naidoo & Anil Amichund Chuturgoon. (2021) Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics. International Journal of Molecular Sciences 22:18, pages 9778.
Crossref
Crossref
Yifeng Yang, Yingxiu Li, Yunlei Hou, Mingze Qin, Ping Gong, Ju Liu & Yanfang Zhao. (2019) Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor. Bioorganic & Medicinal Chemistry Letters 29:23, pages 126666.
Crossref
Crossref
Vishnu C. Damalanka, Scott A. Wildman & James W. Janetka. (2019) Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. MedChemComm 10:9, pages 1646-1655.
Crossref
Crossref
Peng-Cheng Lv, Yu-Shun Yang & Zhong-Chang Wang. (2019) Recent Progress in the Development of Small Molecule c-Met Inhibitors. Current Topics in Medicinal Chemistry 19:15, pages 1276-1288.
Crossref
Crossref
Haoran Yang, Peng Jiang, Dongyan Liu, Hong-Qiang Wang, Qingmei Deng, Xiaojie Niu, Li Lu, Haiming Dai, Hongzhi Wang & Wulin Yang. (2019) Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma. Molecular Therapy - Oncolytics 14, pages 82-93.
Crossref
Crossref
Hongxuan Tong, Yutian Zhu & Yihua Liu. (2019) Incidence and risk of fatigue in cancer patients treated with MET inhibitors. Medicine 98:22, pages e15522.
Crossref
Crossref
Vishnu C. Damalanka, Zhenfu Han, Partha Karmakar, Anthony J. O’Donoghue, Florencia La Greca, Tommy Kim, Shishir M. Pant, Jonathan Helander, Juha Klefström, Charles S. Craik & James W. Janetka. (2018) Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology. Journal of Medicinal Chemistry 62:2, pages 480-490.
Crossref
Crossref
Linxiao Wang, Shan Xu, Xiaobo Liu, Xiuying Chen, Hehua Xiong, Shanshan Hou, Wensheng Zou, Qidong Tang, Pengwu Zheng & Wufu Zhu. (2018) Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents. Bioorganic Chemistry 77, pages 370-380.
Crossref
Crossref
Yu Lu, Kevin P. Cole, Jared W. Fennell, Todd D. Maloney, David Mitchell, Ramesh Subbiah & Balakumar Ramadas. (2018) An Alternative Indazole Synthesis for Merestinib. Organic Process Research & Development 22:3, pages 409-419.
Crossref
Crossref
Palak K. Parikh & Manjunath D. Ghate. (2018) Recent advances in the discovery of small molecule c-Met Kinase inhibitors. European Journal of Medicinal Chemistry 143, pages 1103-1138.
Crossref
Crossref
Linxiao Wang, Shan Xu, Xiuying Chen, Xiaobo Liu, Yongli Duan, Dejia Kong, Dandan Zhao, Pengwu Zheng, Qidong Tang & Wufu Zhu. (2018) Synthesis and bioevaluation study of novel N -methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry 26:1, pages 245-256.
Crossref
Crossref
Lin Xiao Wang, Xiaobo Liu, Shan Xu, Qidong Tang, Yongli Duan, Zhen Xiao, Jia Zhi, Liwen Jiang, Pengwu Zheng & Wufu Zhu. (2017) Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. European Journal of Medicinal Chemistry 141, pages 538-551.
Crossref
Crossref
Jieming Li, Weijie Gu, Xinzhou Bi, Huilan Li, Chen Liao, Chunxia Liu, Wenlong Huang & Hai Qian. (2017) Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry 25:24, pages 6674-6679.
Crossref
Crossref
Ju Liu, Di Yang, Xiuxiu Yang, Minhua Nie, Guodong Wu, Zhunchao Wang, Wei Li, Yajing Liu & Ping Gong. (2017) Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry 25:16, pages 4475-4486.
Crossref
Crossref
Xiaoqiang Wang, Nan Jiang, Sijia Zhao, Shuancheng Xi, Jiao Wang, Tongfei Jing, Wenyu Zhang, Ming Guo, Ping Gong & Xin Zhai. (2017) Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors. Bioorganic & Medicinal Chemistry 25:3, pages 886-896.
Crossref
Crossref
Hong Cui, Xia Peng, Jian Liu, Chunhua Ma, Yinchun Ji, Wei Zhang, Meiyu Geng & Yingxia Li. (2016) Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold. Bioorganic & Medicinal Chemistry Letters 26:18, pages 4483-4486.
Crossref
Crossref
Yingnan Jiang, Ke Zhang, Suyu Gao, Guihua Wang, Jian Huang, Jinhui Wang & Lixia Chen. (2016) Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups. Molecules 21:5, pages 612.
Crossref
Crossref
Muneeb Ahmed, Gaurav Kumar, Marwan Moussa, Yuanguo Wang, Nir Rozenblum, Eithan Galun & S. Nahum Goldberg. (2016) Hepatic Radiofrequency Ablation–induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition. Radiology 279:1, pages 103-117.
Crossref
Crossref
Xin Zhai, Guanglong Bao, Limei Wang, Mingke Cheng, Meng Zhao, Sijia Zhao, Hongyang Zhou & Ping Gong. (2016) Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry 24:6, pages 1331-1345.
Crossref
Crossref
Michael O. Frederick, Joel R. Calvin, Richard F. Cope, Michael E. LeTourneau, Kurt T. Lorenz, Martin D. Johnson, Todd D. Maloney, Yangwei John Pu, Richard D. Miller & Lauren E. Cziesla. (2015)
Development of an NH
4
Cl-Catalyzed Ethoxy Ethyl Deprotection in Flow for the Synthesis of Merestinib
. Organic Process Research & Development 19:10, pages 1411-1417.
Crossref
Crossref
Lisha Chen, Chunlin Li & Yimin Zhu. (2015)
The HGF inhibitory peptide HGP-1 displays promising
in vitro
and
in vivo
efficacy for targeted cancer therapy
. Oncotarget 6:30, pages 30088-30101.
Crossref
Crossref
Xiao-De An, Hongyan Liu, Zhong-Liang Xu, Yi Jin, Xia Peng, Ying-Ming Yao, Meiyu Geng & Ya-Qiu Long. (2015) Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization. Bioorganic & Medicinal Chemistry Letters 25:3, pages 708-716.
Crossref
Crossref
GEPING QU, CHANGTING LIU, BAOJUN SUN, CHANGXI ZHOU, ZHIJIAN ZHANG & PENG WANG. (2014) Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Oncology Reports 32:1, pages 341-347.
Crossref
Crossref
Hideki Yamaguchi, Miho Takanashi, Nachi Yoshida, Yuumi Ito, Reiko Kamata, Kiyoko Fukami, Kazuyoshi Yanagihara & Ryuichi Sakai. (2014)
Saracatinib impairs the peritoneal dissemination of diffuse‐type gastric carcinoma cells resistant to
M
et and fibroblast growth factor receptor inhibitors
. Cancer Science 105:5, pages 528-536.
Crossref
Crossref
Neil J. Kallman, Chin Liu, Matthew H. Yates, Ryan J. Linder, J. Craig Ruble, Eugene F. Kogut, Lawrence E. Patterson, Dana L. T. Laird & Marvin M. Hansen. (2014)
Route Design and Development of a MET Kinase Inhibitor: A Copper-Catalyzed Preparation of an
N
1
-
Methylindazole
. Organic Process Research & Development 18:4, pages 501-510.
Crossref
Crossref
Bálint Szokol, Pál Gyulavári, Ibolya Kurkó, Ferenc Baska, Csaba Szántai-Kis, Zoltán Greff, Zoltán Őrfi, István Peták, Kinga Pénzes, Robert Torka, Axel Ullrich, László Őrfi, Tibor Vántus & György Kéri. (2014) Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Medicinal Chemistry Letters 5:4, pages 298-303.
Crossref
Crossref
Dominic Leiser, Benoît Pochon, Wieslawa Blank-Liss, Paola Francica, Astrid A. Glück, Daniel M. Aebersold, Yitzhak Zimmer & Michaela Medová. (2014) Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS Letters 588:5, pages 653-658.
Crossref
Crossref
Jimin Xu, Jing Ai, Sheng Liu, Xia Peng, Linqian Yu, Meiyu Geng & Fajun Nan. (2014) Design and synthesis of 3,3′-biscoumarin-based c-Met inhibitors. Org. Biomol. Chem. 12:22, pages 3721-3734.
Crossref
Crossref
Sunao Shoji, Mayura Nakano, Haruhiro Sato, Xian Yang Tang, Yoshiyuki Robert Osamura, Toshiro Terachi, Toyoaki Uchida & Koichi Takeya. (2013) The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clinical & Experimental Metastasis 31:1, pages 111-134.
Crossref
Crossref
Shigemitsu Matsumoto, Naoki Miyamoto, Takaharu Hirayama, Hideyuki Oki, Kengo Okada, Michiko Tawada, Hidehisa Iwata, Kazuhide Nakamura, Seiji Yamasaki, Hiroshi Miki, Akira Hori & Shinichi Imamura. (2013) Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Bioorganic & Medicinal Chemistry 21:24, pages 7686-7698.
Crossref
Crossref
Zhe Yu, Yu-chi Ma, Jing Ai, Dan-qi Chen, Dong-mei Zhao, Xin Wang, Yue-lei Chen, Mei-yu Geng, Bing Xiong, Mao-sheng Cheng & Jing-kang Shen. (2013) Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. Acta Pharmacologica Sinica 34:11, pages 1475-1483.
Crossref
Crossref
Yong-Liang Yao, Jie Shao, Chunfu Zhang, Jian-Hong Wu, Qing-Hui Zhang, Jian-Jun Wang & Wei Zhu. (2013) Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS ONE 8:10, pages e78086.
Crossref
Crossref
Andreas Varkaris, Sanchaika Gaur, Nila U. Parikh, Jian H. Song, Farshid Dayyani, Jung-Kang Jin, Christopher J. Logothetis & Gary E. Gallick. (2013) Ligand-independent activation of MET through IGF-1/IGF-1R signaling. International Journal of Cancer 133:7, pages 1536-1546.
Crossref
Crossref
Baohui Qi, Haiyan Tao, Di Wu, Jinying Bai, Yandan Shi & Ping Gong. (2013) Synthesis and Biological Evaluation of 4-Phenoxy-6,7-disubstituted Quinolines Possessing Semicarbazone Scaffolds as Selective c-Met Inhibitors. Archiv der Pharmazie 346:8, pages 596-609.
Crossref
Crossref
Zhongjie Liang, Jing Ai, Xiao Ding, Xia Peng, Dengyou Zhang, Ruihan Zhang, Ying Wang, Fang Liu, Mingyue Zheng, Hualiang Jiang, Hong Liu, Meiyu Geng & Cheng Luo. (2013) Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway. ACS Medicinal Chemistry Letters 4:4, pages 408-413.
Crossref
Crossref
Sven Gunia, Andreas Erbersdobler, Oliver W. Hakenberg, Stefan Koch & Matthias May. (2013) C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathology - Research and Practice 209:4, pages 215-220.
Crossref
Crossref
Dengyou Zhang, Jing Ai, Zhongjie Liang, Wei Zhu, Xia Peng, Xianjie Chen, YinChun Ji, Hualiang Jiang, Cheng Luo, Meiyu Geng & Hong Liu. (2013) Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors. Bioorganic & Medicinal Chemistry Letters 23:8, pages 2408-2413.
Crossref
Crossref
Belnaser A. Busnena, Ahmed I. Foudah, Tina Melancon & Khalid A. El Sayed. (2013) Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer. Bioorganic & Medicinal Chemistry 21:7, pages 2117-2127.
Crossref
Crossref
A. Fasolo, C. Sessa, L. Gianni & M. Broggini. (2013) Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Annals of Oncology 24:1, pages 14-20.
Crossref
Crossref
Yong Wang, Zhong-Liang Xu, Jing Ai, Xia Peng, Jian-Ping Lin, Yin-Chun Ji, Mei-Yu Geng & Ya-Qiu Long. (2013) Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors. Org. Biomol. Chem. 11:9, pages 1545-1562.
Crossref
Crossref
Jo Tucker, Caroline Jochems, James Gulley, Jeffrey Schlom & Kwong Tsang. (2012) Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. Cancers 4:4, pages 1333-1348.
Crossref
Crossref
J. Jean Cui, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish, Hong Shen, Lei Jia, Hengmiao Cheng, Jacqui Hoffman, Phuong Le, Mehran Jalaie, Gilles H. Goetz, Kevin Ryan, Neil Grodsky, Ya-li Deng, Max Parker, Sergei Timofeevski, Brion W. Murray, Shinji Yamazaki, Shirley Aguirre, Qiuhua Li, Helen Zou & James Christensen. (2012)
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1
H
-[1,2,3]triazolo[4,5-
b
]pyrazin-6-yl)-1
H
-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer
. Journal of Medicinal Chemistry 55:18, pages 8091-8109.
Crossref
Crossref
Maria J.W.D. Vosjan, Jo Vercammen, Joost A. Kolkman, Marijke Stigter-van Walsum, Hilde Revets & Guus A.M.S. van Dongen. (2012) Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy. Molecular Cancer Therapeutics 11:4, pages 1017-1025.
Crossref
Crossref